Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And that's you're able to appreciate are enhancing the efficiency and reliability of our company through the revamping of the organization to continue our quest to grow shareholder value as a sustainable and scalable company |
| Our continued focus on increasing demand for the Lap-Band system and recently launched three new sizes of calibration tools will grow revenues |
| There's much look forward to as we move towards 2024 and we are optimistic about the growth potential for the company |
| We believe based on surgeon feedback, that our Lap-Band 2.0 Flex will be a growth catalyst for the company's Lap-Band franchise once approved |
| GLP-1 and other, we call them news is nutrient simulated hormonal therapy are having a tremendous positive impact in that more people than ever are asking about treatment for their obesity |
| We are well positioned with our current FDA approved Lap-Band system, which provides a minimal invasive long-term treatment for obesity and is safe for surgical alternative to more invasive weight loss surgeries |
| That we as a company are uniquely positioned with the least invasive safest and most durable weight option for those patients that have historically had an aversion to medically managed weight loss and surgery |
| So, that's exciting for us |
| And we believe that Biorad, with decades of experience manufacturing distributing medical devices in the vast cell-data the Asia market, potentially reaching approximately 20% to 25% of the world's population, as an ideal partner to expand the reach of our technology |
| Nevertheless it is the highest gross margin percentage in any quarter this year as some of our cost reductions have had a positive impact on gross margins during the third quarter |
| As I mentioned earlier with Lap-Band Louisville, we have seen an increase in the quality of patient needs while successfully reducing costs in targeted markets, for our surgeon advocates operate |
| This software utilizes AI SMS patient self-service technology, which in combination with our targeted direct-to-consumer marketing campaign helps individuals effortlessly overcome new patient intake challenges |
| As we remain optimistic about the long-term growth potential for the company |
| And we have been able to convince many patients with BMIs over 40 that surgery met remains their best option and we're seeing this again in the last six months or so since certainly – since the advent of Wegovy and Mounjaro |
| Additionally, we anticipate receiving FDA approval for the Lap-Band 2.0 Flex late this year or early in 2024 followed by a US product launch that should contribute to increased sales going forward |
| In particular, our exclusive partnership with high medical allows us to advance lead optimization software that can enhance patient engagement and increase patient volume |
| In other words, well first of all we're the 10,000 patients are certainly coming and seeking medical treatments but I'm able to convince those patients with BMIs over 40 over 35 but more than I used to that surgery really is a better option for them |
| The bold steps we have taken to reorganize the company will help to ensure sustainability and scalability |
| We expect this agreement will lay the groundwork catalyzed the successful relaunch and commercialization of the Balloon System in markets worldwide |
| In addition to the necessary cost reduction initiatives related to our first growth pillar, we made significant progress with our newly improved digital lead generation and patient engagement campaign |
| Taken it all together, with actions thus far, we've made significant progress reducing our core operating expenses, cutting approximately $22 million or 70% between 2022 and 2024 |
| Therefore, all the great new newshes that's fantastic, but the primary care providers can't -- they don't have the resources in your practices to prescribe |
| We do remain very confident that with our Lap-Band and expected future offering in the Lap-Band 2.0 Flex |
| This product has been designed with physician feedback in order to improve the patient experience |
| The GLP-1 related big pharma marketing efforts and resulting adoption has helped increase the numbers of people seeking medical attention for this disease, especially by those who have avoided surgery in the past |
| Combination therapy including GLP-1 and uses for those who plateau with their weight loss from bariatric surgery will help individuals get back on track |
| And also once patients are new just yet understand that they can lose weight by altering the gut hormone and they feel so much better |
| Our Board members, customers, consultant advisers, suppliers existing and new shareholders for your continued support of ReShape as we progress on our mission to become the premier physician-led Weight Loss Company |
| I'm sure you are also aware of the growing popularity of GLP-1 agonists that have brought significant benefits to those suffering from type 2 diabetes and help those who are obese |
| As we finish 2023 and move into 2024, we anticipate our revenues increasing and a continued reduction in our operating expenses |
| Statement |
|---|
| The negative effect on quality of life is enormous |
| Growing popularity of GLP-1 prescription drugs for weight loss treatment is the primary reason for the decrease in sales volume in the US and internationally |
| The way you're going to lose more is bariatric surgery until I'm able with all of these patients because of a shortage because of the fact that they realize that they need to be on an injection for the rest of their life or because of they got weight loss |
| What is your expectation? It's obviously impacting sales for the Lap-Band from bariatric procedures as patients and consumers decide tried something new |
| Our revenue totaled $2.2 million for the three months ended September 30, 2023, which represents a reduction of $600,000 compared to the same period in 2020 |
| The decrease in gross profit percentage is due to the decrease in sales volume primarily related to GLP-1 drugs coming to market |
| Gross profit for the three months ended September 30, 2023 was $1.3 million compared to $2.1 million for the same period in 2022, a decrease of $800,000 |
| You lose muscle and fat anyway especially with the more aggressive bariatric surgery procedures like the bypass even the sleeve |
| If the same thing happened with Cardiac surgery, we would say this was negligent, but the problem is overlooked with coping city |
| The COVID numbers went down as you all know are starting to recover and but part of it is most I don't see the decrease in bariatric surgery |
| As Paul mentioned earlier, in November, and in response to continued pressure on the company's revenue caused by the adoption of GLP-1, we are reorganizing the company |
| Because you're losing it so fast |
| And there's also as you discussed there's comorbidities, there is a potential adverse side effects we don't know at what level at this point, right, other than what the studies are showing |
| Or I guess I lost 15 pounds on Wegovy and I want to lose more |
| The sleeve the bypass and the [Indiscernible] diversion, you're losing almost half muscle |
| There's really no doubt |
| Again yet have issues with accessibility, durability, tolerability thereof |
| Obesity is a disease and its many serious complications exert a heavy toll in both human and economic terms |
| Non-GAAP adjusted EBITDA loss was $2.9 million for the three months ended September 30, 2023 compared to a loss of $4.2 million for the same period last year |
| There's a shortage |
Please consider a small donation if you think this website provides you with relevant information